Unknown

Dataset Information

Novel insights into the pathogenesis and treatment of NRAS mutant melanoma.


ABSTRACT:

Introduction

NRAS was the first mutated oncogene identified in melanoma and is currently the second most common driver mutation in this malignancy. For patients with NRASmutant advanced stage melanoma refractory to immunotherapy or with contraindications to immune-based regimens, there are few therapeutic options including low-efficacy chemotherapy regimens and binimetinib monotherapy. Here, we review recent advances in preclinical studies of molecular targets for NRAS mutant melanoma as well as the failures and successes of early-phase clinical trials. While there are no targeted therapies for NRAS-driven melanoma, there is great promise in approaches combining MEK inhibition with inhibitors of the focal adhesion kinase (FAK), inhibitors of autophagy pathways, and pan-R

SUBMITTER: Zhao J 

PROVIDER: S-EPMC8415440 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature